Pulmonx Reports Q3 2026 Revenue Growth and Improved Profitability
Pulmonx Corporation (LUNG) returned to year-over-year revenue growth in the third quarter of 2026, reporting worldwide revenue of $22.8 million, a 6% increase. This growth was supported by a 7% rise in U.S. revenue and a 5% increase in international sales, despite a temporary absence of distributor activity in China. The company demonstrated significant operational improvements, reducing its adjusted EBITDA loss to $3.5 million from $8.2 million in the prior year period. The company's strategic focus on cost realignment and workforce restructuring led to an 18% decrease in operating expenses. Management reiterated its full-year revenue guidance of $90 million to $92 million and raised gross margin expectations to approximately 77%. Additionally, Pulmonx successfully restructured its credit facility to extend debt maturity to 2031, providing enhanced liquidity for future operations.
Tickers: $LUNG
Topics: Cost Reduction EBITDA Improvement Financial Guidance Revenue Growth
Read the full article at Motley Fool
Part of the story Meta Reports Q3 2026 Revenue Growth Amid Legal Settlement and Massive AI Infrastructure Investment (16 articles)